To identify possible genetic interactions between the mechanisms of tumor suppression of menin and pRb, we intercrossed mice with targeted deletions of Men1 and Rb1, and compared tumor development in cohorts of animals carrying single or dual mutations of these tumorsuppressor genes. In mice lacking one copy of Men1, pancreatic islet and anterior pituitary adenomas are common. In animals lacking one copy of Rb1, intermediate pituitary and thyroid tumors occur at high frequency, with less frequent development of pancreatic islet hyperplasia and parathyroid lesions. In mice heterozygous for both Men1 and Rb1, pancreatic hyperplasia and tumors of the intermediate pituitary and thyroid occurred at high frequency. Serum measurements of calcium and glucose did not vary significantly between genotypic groups. Loss of heterozygosity at the Rb1 locus was common in pituitary and thyroid tumors, whereas loss of menin was observed in pancreatic and parathyroid lesions. The tumor spectrum in the double heterozygotes was a combination of pathologies seen in each of the individual heterozygotes, without decrease in age of onset, indicating independent, non-additive effects of the two mutations. Together with the lack of increased tumor spectrum, this suggests that menin and pRb function in a common pathway of tumor suppression.
Introduction
Menin, the tumor suppressor mutated in the syndrome multiple endocrine neoplasia type 1 (MEN1), was initially identified by positional cloning (Chandrasekharappa et al., 1997; Lemmens et al., 1997) . Its lack of similarity to known proteins has confounded speculation regarding its molecular action. Numerous studies have aimed to elucidate menin's function, primarily through investigating its molecular interactions (for a review see Poisson et al., 2003) . Menin binds to a variety of transcription factors (Heppner et al., 2001; Kaji et al., 2001; Chandrasekharappa and Teh, 2003; Sowa et al., 2003) . It has been found to repress JunD-activated transcription (Gobl et al., 1999; Kim et al., 2003) , revealing that, when deprived of menin, JunD switches from growth suppressor to growth promoter (Agarwal et al., 2003) . This suggests that menin acts as a transcriptional corepressor of growthpromoting genes. Menin also binds NF-kB proteins (p50, p52 and p65) and suppresses transcriptional activation by p65 (Heppner et al., 2001) . It is a cofactor for transcription of transforming growth factor beta (TGFb)-responsive genes, via direct interaction with Smad3 (Kaji et al., 2001) . Menin also appears necessary for the commitment of pluripotent mesenchymal stem cells to the osteoblast lineage in response to bone morphogenic protein-2 (BMP-2) by association with Smad1 and Smad5 (Sowa et al., 2004) . The finding that menin is a key regulator of growth inhibitory signals arising from TGFb and BMP pathways reinforces its role as a tumor suppressor, as do its roles in regulation of proliferation (Ratineau et al., 2004) , apoptosis (Schnepp et al., 2004) and genome stability (Jin et al., 2003; Busygina et al., 2004) . Despite this recent progress, a unifying theory of the molecular mode of action of menin as a tumor suppressor is still lacking.
Several MEN1 models have been generated by targeted mutation of the Men1 gene in mice (Crabtree et al., 2001; Bertolino et al., 2003; Loffler et al., 2006) , and in general these effectively mimic the tumor spectrum in humans. Men1 heterozygous mice frequently display hyperplasia and tumors of the endocrine pancreas, anterior pituitary and parathyroid, and at lower frequencies, tumors in the thyroid, testes, ovaries and adrenals (Crabtree et al., 2001; Bertolino et al., 2003; Loffler et al., 2006) . Deregulated activity of the retinoblastoma protein (pRb) has been implicated in many tumors. The Rb1 gene was identified owing to its role in suppressing the development of retinoblastoma (Dunn et al., 1988) , and subsequent studies have shown that pRb plays a key role in regulation of cell-cycle progression (Goodrich et al., 1991; Herrera et al., 1996; Hernando et al., 2004) . Although mice with heterozygous deletion of Rb1 do not usually develop retinoblastoma, they are prone to tumor development in endocrine tissues such as the pituitary (predominantly intermediate lobe) and medullary thyroid (Jacks et al., 1992) . RB1 mutations have been identified in human parathyroid tumors (Cryns et al., 1994) . Although pancreatic islet tumors are not observed in Rb1 þ /À mice, islet carcinomas are observed in crosses of Rb1 þ /À mice with mice carrying heterozygous or homozygous deletion of the Tp53 tumorsuppressor gene (Williams et al., 1994) . Owing to the similarities of the tumor spectra occurring after deletion of either of these tumor-suppressor genes, we sought to examine possible interaction between the molecular pathways of tumor suppression mediated by pRb and menin. We intercrossed mice with targeted deletions of Men1 and Rb1, and compared tumor development in a cohort of dual heterozygous mice (Men1
DX2/ þ ) with that in each of the single tumor-suppressor gene heterozygotes (Men1
Results
Cohorts of mice carrying single or dual mutations of the Men1 and Rb1 genes were euthanised between 210 and 360 days of age. This age period is younger than in previously published work using mice heterozygous for either Rb1 or Men1 (Williams et al., 1994; Crabtree et al., 2001) and was used because: (a) we aimed to look for tumors that arose at an earlier age and were more aggressive owing to the potential cooperative effect of the dual heterozygotes and (b) the reduced mean age of survival of the Rb1 heterozygous mice compared with Men1 heterozygotes. Gross abnormalities in the primary affected organs observed at the time of necropsy are summarized in Table 1 , with histopathology observations listed in Table 2 . There was no obvious difference in survival rate of the dual heterozygous animals (Men1 þ /À ;Rb1 DX2/ þ ; n ¼ 34) compared to the animals with only single heterozygous mutations (Men1
DX2/ þ animals with at least two observed lesions at necropsy was significantly more than in Men1 þ /À ;Rb1 þ / þ animals (Po0.001) but was not significantly different from Men1 þ / þ ;Rb1 DX2/ þ animals (P ¼ 0.244, Table 1 ). The lesions seen in Men1
DX2/ þ animals were predominantly observed in the thyroid(s) and pituitary, similar to Men1 þ / þ ;Rb1 DX2/ þ animals ( Table 1 ). In Men1
þ / þ animals, multiple lesions were generally found in the pancreas and pituitary (Table 1) . Histological assessment indicated no significant difference in severity or number of tumors between the dual heterozygotes and animals harboring only a single heterozygous mutation (Table 2 ). In 13 Men1
animals for which histology was assessed, 69% developed pancreatic islet lesions, with two animals showing adenoma (15%) and seven hyperplasia (54%; Table 2 ). In the dual heterozygous animals, hyperplasia was evident in 10 of 18 animals (56%) and one animal of this cohort developed an adenoma (Table 2 ). Similar to the dual heterozygotes and Men1
DX2/ þ animals showed evidence of pancreatic hyperplasia (8/15); however, there was no evidence of adenoma in these animals ( Table 2) . Immunohistochemical detection of insulin and glucagon confirmed that the enlarged islets observed in dual heterozygotes were producing predominantly insulin, with occasional hyperplastic islets staining strongly with glucagon, consistent with observations in Men1 þ /À animals ( Figure 1a ). Gastrin immunoreactivity was not observed in islets from dual heterozygotes (data not shown).
The pituitary was affected in all three mouse genotypes, albeit in different regions. In the dual Men1 
predominantly from the intermediate lobe, the former genotype also having some anterior pituitary tumors (Table 2) . Conversely, pituitary abnormalities in Men1
þ / þ mice originated exclusively from the anterior lobe (Table 2) Table 2 .
Of the 18 Men1 þ /À ;Rb1
animals for which thyroid histology was assessed, adenomas were evident in 17 of these animals (94%, Table 2 ). Similarly, adenomas were observed histologically in 71% of (Table 2 ). In Men1
þ / þ animals thyroid pathology was much less severe and adenoma was observed in only two of 13 samples ((15%) ( Table 2) ). Of 14 Men1 þ / þ ;Rb1 þ / þ animals for which thyroid histology was assessed, one showed agerelated changes typified by non-uniform follicle enlargement, whereas all others were normal. Figure 1c shows examples of thyroid histology from mice of each genotype, with similar large tumors seen in Men1
animals, whereas normal thyroid architecture was apparent in the majority of Men1
animals. The thyroid origin of the tumors was confirmed by immunohistochemical detection of thyroglobulin ( Figure 1c ) and lack of parathyroid hormone expression (data not shown). Although there is a difference in the occurrence of thyroid tumors between the three genotype groups, the rates of parathyroid lesions (Men1 Table 2 ) were not significantly different (P>0.95). Surprisingly, a small number of wild-type mice were observed to have parathyroid tumors at the time of necropsy; however, the reason for this is unknown.
Adrenal gland pathology (bilateral cortical adenoma) was seen in only one animal (Men1
þ / þ ) in the current study (data not shown). Other tumors not commonly associated with syndromic MEN1 were observed in some animals. For example, Leydig cell adenomas were observed in one Men1
DX2/ þ animals and thymic hyperplasia was evident in one female Men1
animal (data not shown). Other age-related pathologies, such as lymphoma in the spleen, or enlargement of the seminal vesicles, were also noted in very few animals, including wild-type controls (data not shown).
Loss of heterozygosity (LOH) analysis indicated that almost all pancreatic lesions in dual heterozygotes had lost the normal Men1 allele (Figure 2a) . Consistent with the predominantly intermediate lobe origin, most pituitary tumors from Men1 þ /À ;Rb1 DX2/ þ animals had lost wild-type Rb1 (Figure 2b ), but one anterior pituitary tumor lost Men1 (Figure 2c ). Thyroid lesions were observed to have lost the wild-type Rb1 allele (Figure 2d ). The very small size of the parathyroid lesions observed in this study precluded the use of the same polymerase chain reaction (PCR)-based approach to detection of LOH. Using immunofluorescence, we did detect loss of menin in parathyroid lesions. Figure 3 shows a cluster of dysplastic cells within the parathyroid gland of a Men1
animal, which have lost nuclear menin immunoreactivity, whereas surrounding cells retain menin expression. Nuclear menin 
immunoreactivity was observed in morphologically normal pancreatic islets from Men1 þ /À ;Rb1 DX2/ þ animals (data not shown), but in hyperplastic islets reactivity was lost from some islet cells (Figure 3) , consistent with the LOH observed by PCR (data not shown).
No significant differences in serum calcium concentration were observed between any of the genotype groups, after exclusion of a single obvious outlier from a Men1 þ /À ;Rb1 DX2/ þ animal with a measured serum calcium concentration of 3.53 mmol/l (Studentized residual value >3; Figure 4 ; analysis of variance (ANOVA)). Levels of serum glucose also did not vary significantly between genotype groups ( Figure 5 ; ANO-VA). As these parameters were measured only in the younger cohorts of mice, it remains possible that in older animals, in which larger pancreatic and parathyroid/ thyroid tumors were more frequently observed, there may have been more substantial variation in observed calcium or glucose levels.
Discussion
Although homozygous deletion of either Men1 or Rb1 tumor-suppressor genes in mice results in embryonic lethality, in a heterozygous state single mutants are viable and fertile but prone to development of tumors, predominantly in endocrine organs (Jacks et al., 1992; Loffler et al., 2006) . Pituitary adenoma development is a common feature of both Men1 þ /À and Rb1 DX2/ þ single heterozygotes. In Men1 þ /À animals, these tumors usually arise from the anterior pituitary and are most frequently prolactinomas, whereas in Rb1 þ /À models including these Rb1 DX2/ þ mice, pituitary tumors are very common and generally originate from the intermediate lobe, producing ACTH. Dual heterozygous mice (Men1
DX2/ þ ) are also viable and apparently healthy until at least 6 months of age. Deletion of single copies of both Men1 and Rb1 in mice therefore does not phenocopy the embryonic lethality observed in complete knockouts of either gene, indicating that there is no synergistic effect of the two deletions in embryogenesis. We have seen a predisposition to tumorigenesis in adult Men1
DX2/ þ animals, in sites mirroring those seen in each of the two individual mutants. On the basis of location, endocrine activity and LOH, the tumors observed in the pituitaries of Men1
DX2/ þ animals are predominantly attributable to the loss of pRb. The simultaneous reduction of menin dosage in these intermediate pituitary lesions did not have a marked effect on frequency, age of onset or severity, 
animals. Standard H&E, and immunohistochemical detection of insulin and glucagon in nearby sections as indicated. (b) Pituitary histopathology of Men1
þ /À ; Rb1 þ / þ (12-month-old female), Men1 þ /À ;Rb1 DX2/ þ (7-month-old male) and Men1 þ / þ ;Rb1 DX2/ þ (7.8-month-old female) and littermate control Men1 þ / þ ;Rb1 þ / þ (7-month-old male) animals. Standard H&E staining and immunohistochemical detection of prolactin (PRL) and ACTH in nearby sections as indicated. (c) Thyroid histopathology of male Men1
(9 months), and Men1 þ / þ ;Rb1 DX2/ þ (11 months) and littermate control Men1 þ / þ ;Rb1 þ / þ (12 months) animals. Standard H&E staining and immunohistochemical detection of thyroglobulin in nearby sections as indicated. Scale bars represent 0.5 mm.
demonstrating no augmentation when Men1 is also deleted from this tissue.
In our previous study, 21% of 1-year-old Men1 þ /À animals developed anterior pituitary tumors (Loffler et al., 2006) . In the present study, we observed such lesions in 2/13 Men1 þ /À ;Rb1 þ / þ mice (16%). Although there is an increase in frequency of anterior lobe pituitary tumors in the Men1
þ / þ mice (16%), the difference is not significant (P>0.2). It is likely that the early and more aggressive development of tumors originating from the intermediate lobe, owing to the deletion of Rb1, substantially masks the contribution of Men1 to the development of anterior pituitary prolactinomas in Men1 þ /À ;Rb1 DX2/ þ animals. A difference in rates of pituitary tumorigenesis in male and female Men1 þ /À animals has been noted previously (Loffler et al., 2006) , and confirmed by a similar trend in the Men1
þ / þ cohort in the present study (30% of females versus 10% of males). This difference, however, was not apparent in the overall rate of gross pituitary pathology in Men1
animals, possibly masked by the more severe phenotype associated with loss of Rb1.
Thyroid tumors are seen at high frequency in animals with heterozygous loss of Rb1 (Jacks et al., 1992) , including the line described here, and less severe thyroid tumors are also seen in many aging Men1 þ /À animals (Loffler et al., 2006) . We have observed gross thyroid lesions and in many cases large tumors in Men1
animals. The similar rates in the two groups indicate that the severe thyroid pathology associated with loss of Rb1 is not significantly exacerbated by the reduction of Men1 dosage. The primary role for pRb in thyroid tumorigenesis is also reinforced by the observation of LOH at the Rb1 locus in these tumors from Men1
Conversely, it appears that the major effector in the development of pancreatic islet hyperplasia and adenoma is menin, as we have not observed any substantial increase in frequency or severity in Men1
animals (69%) at the same age (Table 2) . Pancreatic islet pathology has been the most common pathology observed in several mouse models of MEN1 (Crabtree et al., 2001; Bertolino et al., 2003; Loffler et al., 2006) . In our previous analysis of the line of Men1 þ /À mice used here, we have observed the development of pancreatic islet hyperplasia and adenoma with high frequency from approximately 9 months of age, with severity increasing in animals over 1 year old (Loffler et al., 2006) . Pancreatic islet tumors are not commonly seen in mice lacking one copy of Rb1 (Jacks et al., 1992) . We did not find an increase of islet adenomas in the Men1
animals (5 versus 15%, respectively), in contrast to the effect of simultaneous loss of Rb1 and p53 (Williams et al., 1994; Casanovas et al., 2005) . Williams et al. (1994) also observed development of pinealoblastoma and sarcoma in Rb1
animals. No evidence of these tumor types has been observed in the current study. Parathyroid adenoma is the most common observation in human MEN1, and we have previously observed parathyroid hyperplasia or adenoma in some Men1 þ /À animals, particularly over 15 months of age (Loffler et al., 2006) . As expected, the rate of parathyroid pathology in all genotype groups in the current cohort is lower, as these animals were killed at earlier time points. There was no substantial increase in severity or earlier onset in the Men1 Table 2 ), indicating that simultaneous loss of pRb does not appear to impact the course of parathyroid disease in these animals, similar to our observations in the pancreas. The same appears true in the adrenal glands, testes and ovaries.
Deletion of Rb1 in conjunction with another tumorsuppressor gene can lead to an increased tumor spectrum, earlier tumor onset and decreased survival (Williams et al., 1994; Park et al., 1999) . It is widely accepted that the effects of such dual deletions exacerbate the tumor spectra and/or severity of tumors compared to a single deletion owing to the two tumorsuppressor genes acting via different cellular pathways.
The data presented here demonstrate that there is no augmentation of tumor spectrum or severity in dual Men1
DX2/ þ animals compared to animals with only a single heterozygous mutation (Men1
Rather, the combination of pathologies of the single heterozygotes is observed in the dual heterozygotes. Although this could indicate that Men1 does not play a significant role in tumor suppression in lesions that arise selectively in Rb1 DX2/ þ mice and vice versa, the fundamental requirement for both pRb and menin in cell-cycle regulation makes this unlikely. Further, both Men1 þ /À ;and Rb1 þ /À mice have been observed to develop thyroid tumors (Jacks et al., 1992; Crabtree et al., 2001; Bertolino et al., 2003; Loffler et al., 2006) , yet no augmentation of tumor severity or decrease in age of onset of thyroid lesions was observed in Men1 þ /À ;Rb1 DX2/ þ mice. We therefore conclude that menin and pRb act in a common molecular pathway of cell-cycle regulation and tumor suppression. Support for this notion comes from the recent finding that menin suppresses pancreatic islet tumor development by maintaining the expression of the cyclin-dependent kinase (CDK) inhibitors p27 and p18 (Karnik et al., 2005) . These CDK inhibitors are well-characterized negative regulators of the cell cycle that act by maintaining pRb in an active hypophosphorylated state. The regulation of these CDK inhibitors by menin thus provides a link between the activities of pRb and menin, in keeping with our observations in Men1
Materials and methods
Mice with targeted deletion of exon 2 of Men1 (Biondi et al., 2002; Loffler et al., 2006) , and with constitutive deletion of exon 2 of Rb1 (Rb1
DX2/DX2
, Tonks et al., 2005) have been described previously. Heterozygous animals of these two lines of mice were intercrossed on a C57/129 background to yield offspring bearing heterozygous deletions of both tumorsuppressor genes (Men1
. Viable offspring of each of the expected genotype combinations were born in approximately expected Mendelian ratios with no evidence of gross pathology or morbidity in newborn and juvenile animals. Individual animals were genotyped by PCR as reported previously (Biondi et al., 2004; Tonks et al., 2005) . Animals were housed under standard conditions as approved by the Queensland Institute of Medical Research Animal Ethics Committee until morbidity was noted or until reaching predetermined ages for study.
Thirty-four dual heterozygous Men1
;Rb1 DX2/ þ mice were included in the current study (17 female, 17 male; median age 275 days, range 213-385 days). These were compared to 40 Men1
þ / þ animals (20 female, 20 male; median age 272 days, range 210-418 days), 35 Men1 þ / þ ;Rb1 DX2/ þ animals (17 female, 18 male; median age 272 days, range 210-508 days) and 33 Men1 þ / þ ;Rb1 þ / þ wild-type control littermates (11 female, 22 male; median age 276 days, range 210-507). Full necropsies carried out and any observed gross pathology noted.
Blood was collected from animals killed at 7 and 9 months by cardiac puncture. Serum was frozen on dry ice and stored at À801C. Total calcium and glucose concentrations were measured using the standard detection kits (Roche Diagnostics, Mannheim, Germany) at the Queensland Health Pathology and Scientific Services, Division of Chemical Pathology, at the Royal Brisbane and Women's Hospital, Herston, Australia.
Tissues were fixed in 10% neutral-buffered formalin, then stored in 70% ethanol or processed for histology at the Queensland Institute of Medical Research/University of Queensland Joint Histotechnology Facility. Hematoxylin and eosin-stained (H&E) sections were assessed by a pathologist (PW or HKM) who was blinded to age and genotype of the animals. Pancreatic islets, anterior and intermediate pituitary, thyroid and parathyroid, and in some animals also the adrenals and gonads were scored as normal, hyperplastic or adenomatous. Hyperplasia refers to an increase in organ size owing to an increase in normal cell number with maintenance of cellular relationships. Adenoma refers to benign glandular neoplasms that are well-circumscribed islands of cells separated by stromal connective tissue from other cells. Any other gross pathology noted at necropsy was also assessed by histology. In each case, the most severe observed pathology was scored, for example, a pancreas with multiple hyperplastic islets and one adenoma was scored as adenoma, or a thyroid in which non-uniform follicle enlargement and adenoma were present was scored as adenoma.
Tissues from a subset of animals were selected for hormone immunohistochemistry, in which case serial 5 mm paraffin sections were mounted on Superfrost plus slides. Insulin, glucagon, prolactin and ACTH were detected as described previously (Biondi et al., 2004; Loffler et al., 2006) . Thyroglobulin (Dako, Glostrup, Denmark M 0781, 1:100) was detected using the Dako Envision þ secondary system, diaminobenzidine (DAB) staining, and counterstained with hematoxylin.
To confirm genotype and assess LOH at the Men1 or Rb1 loci in tumors, tissue collected at necropsy was genotyped according to the PCR protocol described above. LOH of Men1 or Rb1 was assessed in formalin-fixed pancreatic islet adenomas from eight randomly selected Men1 þ /À ;Rb1 DX2/ þ mice. At least two adenomas were isolated from each mouse and genomic DNA extracted as described previously (Biondi et al., 2004) . Tissue from pituitary and thyroid tumors was isolated by manually scraping the tumor material from a 5 mm section using a scalpel and collected into a 1.5 ml sterile microfuge tube. Tissue from a nearby site or from the contralateral paired organ, if normal, was collected simultaneously for control purposes. DNA was extracted using the QIAamp Micro DNA kit (QIAGEN, Hilden, Germany) as per the manufacturer's protocol for 'Isolation of genomic DNA from Laser-Microdissected tissues'. PCR was then carried out using primers: 1023F, 5 0 -CGGGTAGAGATTGTAGGGACT GG-3 0 , 2001R, 5 0 -CTGGGACTGTTGAAAGACTGGGG-3 0 and 1161R, 5 0 -CTGAGACCCTTCAACCAAGGC-3 0 to amplify both the wild-type and targeted Men1 allele in the same tube using the conditions described previously (Biondi et al., 2004) . Wild-type and deleted exon 2 alleles of Rb1 were detected using primers: Rb1Fa, 5 0 -CCAGGTTATAGTCTATCATAA TAGGG-3 0 , Rb2, 5 0 -ACCTAGCCTGAGAGTAGGC-3 0 and Rb5, 5 0 -GGTCCTTCAATTTCTAGCC-3 0 , under 'touchdown' conditions with annealing temperatures between 60 and 53.51C, for a total of 35 cycles. Products were visualized on 2% agarose containing ethidium bromide. Relative levels of wild-type and targeted allele products in the tumor and control samples were determined by densitometry (ImageQuaNT, version 4.2a, Molecular Dynamics, Buckinghamshire, England, UK). Reduction of wild-type band intensity by 50% compared to the targeted allele was considered indicative of LOH.
Menin was detected by immunofluorescence in formalinfixed paraffin sections after retrieval in 10 mM citrate buffer, pH 6.0, for 7.5 min at 1251C, using anti-menin polyclonal antibody (Bethyl Labs, Montgomery, Texas, USA) at a dilution of 1:150, then rhodamine-conjugated anti-rabbit secondary antibody (Jackson Labs, Westgrove, PA, USA). Sections were mounted with Vectashield including DAPI, photographed using a Zeiss Axioskop 2 Mot Plus, and images assembled using Axiovision software (Carl Zeiss Vision, Jena, Germany).
Statistical analyses were carried out using SPSS version 13 (SPSS Inc, Chicago, IL, USA). Pathology categories were compared using a Pearson w 2 -test, or Fisher's exact test if values of 5 or below were included. Serum glucose and calcium levels were compared by ANOVA.
